Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WuXi PharmaTech Founder Ge Li Says Upcoming Merger With Charles River Is Part Of Globalization Of The Drive To Save Lives

This article was originally published in PharmAsia News

Executive Summary

BEIJING - The chief executive officer of Shanghai-headquartered WuXi PharmaTech, Ge Li, said that a planned merger with Massachusetts-based contract research organization Charles River could help spark a "revolution" in early-stage drug research in China
Advertisement

Related Content

Fresh Off BMS Deal, Leading Chinese CRO WuXi PharmaTech Outlines Plan To Expand Biologics Business To Keep Pace With Big Pharma
Charles River Abandons WuXi PharmaTech Just Days Before Crucial Shareholder Votes On Planned Merger
Charles River Drops WuXi PharmaTech Days Before Crucial Shareholder Vote; What Does the Future Hold For Both Firms?
Charles River, WuXi PharmaTech CEOs Issue Joint Appeal For Shareholder Support
Impromptu Objections Filed With SEC Could Threaten Charles River's Proposed Merger With China's Leading CRO
Transferring Early-stage Drug, Biologics Research From West To East Will Speed Up Over Next Five Years
New Approaches To Innovation Needed To Reach Globe's Poor At The "Bottom Of The Pyramid" - And To Fend Off Emerging Competitors Around The World
US-India Healthcare Summit: New Business Models Needed To Reach the World's Poor
BIO Welcomes First Chinese Members: Shanghai Zhangjiang Park And Taizhou Medical City
Charles River To Merge With Leading Chinese Drug CRO WuXi PharmaTech If $1.6 Billion Transaction Is Approved By Beijing's Antitrust Czars
Advertisement
UsernamePublicRestriction

Register

SC074701

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel